The VKORC1 and CYP2C9 genotypes are associated with over-anticoagulation during initiation of warfarin therapy in children

J Thromb Haemost. 2013 Feb;11(2):373-5. doi: 10.1111/jth.12072.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Age Factors
  • Anticoagulants / administration & dosage
  • Anticoagulants / adverse effects
  • Anticoagulants / blood
  • Anticoagulants / pharmacokinetics*
  • Aryl Hydrocarbon Hydroxylases / genetics*
  • Aryl Hydrocarbon Hydroxylases / metabolism
  • Biotransformation
  • Blood Coagulation / drug effects*
  • Child
  • Child, Preschool
  • Cross-Sectional Studies
  • Cytochrome P-450 CYP2C9
  • Drug Monitoring / methods
  • England
  • Female
  • Gene Frequency
  • Genetic Predisposition to Disease
  • Hemorrhage / chemically induced
  • Hemorrhage / genetics
  • Humans
  • Infant
  • International Normalized Ratio
  • Male
  • Mixed Function Oxygenases / genetics*
  • Mixed Function Oxygenases / metabolism
  • Ontario
  • Pharmacogenetics
  • Phenotype
  • Retrospective Studies
  • Risk Factors
  • Vitamin K Epoxide Reductases
  • Warfarin / administration & dosage
  • Warfarin / adverse effects
  • Warfarin / blood
  • Warfarin / pharmacokinetics*

Substances

  • Anticoagulants
  • Warfarin
  • Mixed Function Oxygenases
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • VKORC1 protein, human
  • Vitamin K Epoxide Reductases